Target intelligence / Profile preview

Commensal human microbiota

Molecular classification
Other (microbial community, not a single molecular entity)
01

Overview

Commensal human microbiota refers to the vast ecological community of bacteria, archaea, fungi, viruses, and other microbes inhabiting human tissues and biofluids, including the gastrointestinal tract, skin, and other anatomically-defined sites. These microbes contribute to vital physiological processes including digestion, metabolism, immune regulation, and protection against pathogens. While commensal, many members of the microbiota have mutualistic relationships with the host, meaning both parties benefit. The overall composition is influenced by genetics, diet, age, environment, and health status. Disruption of this ecosystem (dysbiosis) is implicated in numerous diseases, and manipulation of the microbiota through probiotics, antibiotics, or fecal microbiota transplantation has become a therapeutic strategy, especially for recurrent gastrointestinal infections and other chronic conditions. The commensal human microbiota is a collective rather than a single therapeutic target, and current research seeks to define the specific roles and optimal modulation strategies of the myriad species that comprise it

Other names
normal floranormal microbiotacommensal microbiomebeneficial microbiota
02

Mechanism of action

Additive: supplementing with beneficial microbes (probiotics, FMT); Subtractive: elimination of pathogenic or undesired microbes (antibiotics, phage therapy); Modulatory: altering activity/composition via diet, prebiotics, or other agents

03

Biological functions

DigestionMetabolismImmune regulationProtection against pathogensRegulation of host homeostasis
04

Disease associations

Infection (implicated when dysbiosis occurs)InflammationCancer (some links to cancer risk or modulation)Metabolic diseases (obesity, diabetes, etc.)Neuropsychiatric and neurodegenerative diseases (via gut-brain axis)Other (broader implications for chronic and infectious diseases)
05

Safety considerations

Risk of introducing pathogens during microbiota transplantationAntibiotic resistance developmentOpportunistic infections when microbiota disruptedUnintended effects/collateral changes resulting from broad manipulation of microbiota
06

Interacting drugs

Antibiotics (disrupt overall microbiota)

4 more in the full profile.

07

Biomarkers

Microbial composition by 16S rRNA gene sequencingSpecific microbial metabolites (e.g., short-chain fatty acids, trimethylamine N-oxide)Microbial diversity indicesPresence/abundance of key beneficial or pathogenic taxa

Beyond the preview

Go deeper on Commensal human microbiota.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Commensal human microbiota.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call